Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?

(2022) James W. Smithy et al.   Cancer Discovery

A Pilot Study of Short-course Nivolumab and Low-dose Ipilimumab for Adjuvant Treatment of Melanoma

(2021) Maria Constantinou et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

(2021) Alexander MM. Eggermont et al.   EUROPEAN JOURNAL OF CANCER

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2021) Kenneth F. Grossmann et al.   Cancer Discovery

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Lisa Zimmer et al.   LANCET

Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B

(2020) Matteo S. Carlino et al.   CLINICAL CANCER RESEARCH

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

(2020) Paolo Antonio Ascierto et al.   Journal for ImmunoTherapy of Cancer

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

(2020) Paolo A Ascierto et al.   LANCET ONCOLOGY

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

(2019) Celeste Lebbé et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

(2019) Elisa A Rozeman et al.   LANCET ONCOLOGY

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

(2018) G V Long et al.   ANNALS OF ONCOLOGY

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

(2017) Mark B. Faries et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

(2013) Y. Feng et al.   CLINICAL CANCER RESEARCH